The secure cloud services will be used to transmit device telemetry data from physician and company sites in Sweden, the UK and the US back to Aerocrine for analyses.
Aerocrine intends to use this information to deploy its field resources for customer service and sales support in the future.
Aerocrine CEO Scott Myers said the ability to collect vital telemetry data from deployed devices has been a key objective of the company.
"A cloud-based solution allowing us to collect data on device performance in real-time helps us to be more proactive in our customer support and ensure that our NIOX devices help the physicians deliver the best possible outcome for the patient," Myers added.
For this pilot project, proof of concept will be carried out in this fall, and data will be collected from Aerocrine devices deployed in Sweden, the UK and the US.
In the first phase, Microsoft will connect the Aerocrine devices to its secure cloud analytics platform, Microsoft Azure, to demonstrate the secure and accurate transmission of telemetry data.
Microsoft Sweden industry marketing development manager Mathias Ekman said: "We are excited to work with Aerocrine on this project as part of the CityNext, Healthier Cities initiative to show the potential of new technology to drive productivity and patient safety as we move towards a mobile-first and cloud-first world."
Aerocrine produces NIOX MINO and NIOX VERO products, which will be used in the diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma.
Image: Aerocrine’s NIOX MINO. Photo: courtesy of Aerocrine AB.
